Imugene Ltd

Company Profile

• Business description

  Imugene Ltd is an Australian-headquartered clinical stage cell therapy company developing an Allogeneic CAR T for blood cancers. Its lead asset is an off-the-shelf (allogeneic) cell therapy CAR T drug azer-cel (azercabtagene zapreleucel) which targets CD19 to treat blood cancers. The lead asset, azer-cel, is an allogeneic CAR T cell therapy targeting CD19 positive cancer cells. Autologous CAR T therapies, which use the patient's own modified T cells, azer-cel uses donor-derived T cells that are genetically engineered to attack cancer cells. The group has identified one reportable segment, being the research and development of new treatments that seek to activate the immune system of cancer patients to identify and eradicate tumours.

• Contact

  4-6 Bligh Street
  Suite 12.01, Level 12
  SydneyNSW2000
  AUS

  T: +61 294230881

  https://www.imugene.com

• Sector

  Healthcare

  Stock type

  Defensive

• Industry

  Biotechnology

  Fiscal Year End

  Employees

  5